200 related articles for article (PubMed ID: 10845810)
21. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats.
Dragan YP; Shimel RJ; Bahnub N; Sattler G; Vaughan JR; Jordan VC; Pitot HC
Toxicol Sci; 1998 Jun; 43(2):129-38. PubMed ID: 9710954
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.
Yao D; Zhang F; Yu L; Yang Y; van Breemen RB; Bolton JL
Chem Res Toxicol; 2001 Dec; 14(12):1643-53. PubMed ID: 11743747
[TBL] [Abstract][Full Text] [Related]
23. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
[TBL] [Abstract][Full Text] [Related]
24. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro.
Hemminki K; Widlak P; Hou SM
Carcinogenesis; 1995 Jul; 16(7):1661-4. PubMed ID: 7614704
[TBL] [Abstract][Full Text] [Related]
25. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
[TBL] [Abstract][Full Text] [Related]
26. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.
Carthew P; Lee PN; Edwards RE; Heydon RT; Nolan BM; Martin EA
Arch Toxicol; 2001 Aug; 75(6):375-80. PubMed ID: 11570696
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.
Wiebe VJ; Benz CC; Shemano I; Cadman TB; DeGregorio MW
Cancer Chemother Pharmacol; 1990; 25(4):247-51. PubMed ID: 2136809
[TBL] [Abstract][Full Text] [Related]
28. Understanding the genotoxicity of tamoxifen?
Phillips DH
Carcinogenesis; 2001 Jun; 22(6):839-49. PubMed ID: 11375888
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen.
Martin EA; Carthew P; White IN; Heydon RT; Gaskell M; Mauthe RJ; Turteltaub KW; Smith LL
Carcinogenesis; 1997 Nov; 18(11):2209-15. PubMed ID: 9395223
[TBL] [Abstract][Full Text] [Related]
30. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry.
White IN; Martin EA; Mauthe RJ; Vogel JS; Turteltaub KW; Smith LL
Chem Biol Interact; 1997 Sep; 106(2):149-60. PubMed ID: 9366900
[TBL] [Abstract][Full Text] [Related]
32. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
O'Regan RM; Cisneros A; England GM; MacGregor JI; Muenzner HD; Assikis VJ; Bilimoria MM; Piette M; Dragan YP; Pitot HC; Chatterton R; Jordan VC
J Natl Cancer Inst; 1998 Oct; 90(20):1552-8. PubMed ID: 9790548
[TBL] [Abstract][Full Text] [Related]
33. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
di Salle E; Zaccheo T; Ornati G
J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
[TBL] [Abstract][Full Text] [Related]
34. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver.
Hashiba M; Kasahara T; Kim SY; Shibutani S; Degawa M
Cancer Sci; 2006 Jun; 97(6):468-77. PubMed ID: 16734724
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
Hemminki K; Rajaniemi H; Lindahl B; Moberger B
Cancer Res; 1996 Oct; 56(19):4374-7. PubMed ID: 8813128
[TBL] [Abstract][Full Text] [Related]
36. Initiating activity of the anti-estrogen tamoxifen, but not toremifene in rat liver.
Williams GM; Iatropoulos MJ; Karlsson S
Carcinogenesis; 1997 Nov; 18(11):2247-53. PubMed ID: 9395228
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the major DNA adducts in the liver of rats chronically exposed to tamoxifen for 18 months.
Firozi PF; Vulimiri SV; Rajaniemi H; Hemminki K; Dragan Y; Pitot HC; DiGiovanni J; Zhu YH; Li D
Chem Biol Interact; 2000 Apr; 126(1):33-43. PubMed ID: 10826652
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
[TBL] [Abstract][Full Text] [Related]
39. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo.
Moorthy B; Sriram P; Randerath E; Randerath K
Biochem Pharmacol; 1997 Mar; 53(5):663-9. PubMed ID: 9113085
[TBL] [Abstract][Full Text] [Related]
40. DNA adduct formation by tamoxifen and structurally-related compounds in rat liver.
Rajaniemi H; Mäntylä E; Hemminki K
Chem Biol Interact; 1998 May; 113(2):145-59. PubMed ID: 9717515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
